Latest Ratios: P/E Ratio -6.4x · EV/EBITDA 18.6x · ROE -24.5%. (1996–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $5.7B | $5.5B | $8.4B | $11.8B | $11.8B | $15.6B | $19.5B | $17.7B | $12.1B | $11.6B | $7.7B |
| Enterprise Value | $8.1B | $7.8B | $9.8B | $13.5B | $13.3B | $17.1B | $21.7B | $19.4B | $13.9B | $13.5B | $8.2B |
| P/E Ratio → | -6.41 | — | 120.26 | 33.11 | 32.50 | 32.11 | 58.05 | 38.41 | 60.25 | 76.09 | 32.36 |
| P/S Ratio | 2.88 | 2.74 | 2.75 | 3.97 | 4.23 | 5.54 | 7.67 | 6.83 | 4.94 | 5.41 | 4.11 |
| P/B Ratio | 1.86 | 1.75 | 1.96 | 2.66 | 2.94 | 4.15 | 5.83 | 5.95 | 4.76 | 4.78 | 3.59 |
| P/FCF | 23.40 | 22.24 | 16.46 | 28.14 | 44.91 | 26.87 | 56.30 | 52.63 | 33.93 | 33.27 | 21.61 |
| P/OCF | 16.86 | 16.02 | 13.18 | 23.10 | 34.52 | 23.92 | 44.60 | 40.33 | 27.66 | 27.65 | 18.80 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 3.91 | 3.23 | 4.54 | 4.78 | 6.09 | 8.53 | 7.49 | 5.68 | 6.30 | 4.37 |
| EV / EBITDA | 18.63 | 17.97 | 23.14 | 18.04 | 18.28 | 19.76 | 33.29 | 30.31 | 26.14 | 25.64 | 18.68 |
| EV / EBIT | 31.57 | 62.44 | 61.92 | 26.00 | 26.69 | 27.74 | 51.04 | 46.26 | 43.08 | 36.81 | 27.17 |
| EV / FCF | — | 31.74 | 19.33 | 32.20 | 50.77 | 29.49 | 62.63 | 57.70 | 38.98 | 38.76 | 22.99 |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 56.2% | 56.2% | 55.9% | 55.4% | 54.9% | 55.2% | 52.2% | 54.3% | 56.5% | 54.6% | 53.3% |
| Operating Margin | 12.8% | 12.8% | 5.0% | 17.0% | 17.9% | 22.4% | 16.7% | 16.5% | 13.1% | 17.3% | 17.1% |
| Net Profit Margin | -45.4% | -45.4% | 2.3% | 12.0% | 13.0% | 17.3% | 13.2% | 17.8% | 8.2% | 7.1% | 12.7% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -24.5% | -24.5% | 1.6% | 8.4% | 9.3% | 13.7% | 10.6% | 16.7% | 8.1% | 6.7% | 11.4% |
| ROA | -12.9% | -12.9% | 1.0% | 4.9% | 5.3% | 6.9% | 5.0% | 7.3% | 3.2% | 3.0% | 6.1% |
| ROIC | 3.4% | 3.4% | 1.9% | 6.5% | 6.9% | 8.7% | 6.2% | 7.1% | 5.6% | 8.0% | 8.9% |
| ROCE | 4.0% | 4.0% | 2.3% | 7.6% | 8.0% | 9.8% | 6.8% | 7.5% | 5.6% | 8.1% | 9.6% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.87 | 0.87 | 0.41 | 0.43 | 0.46 | 0.52 | 0.77 | 0.67 | 0.85 | 0.93 | 0.48 |
| Debt / EBITDA | 6.29 | 6.29 | 4.12 | 2.57 | 2.51 | 2.27 | 3.94 | 3.13 | 4.06 | 4.26 | 2.36 |
| Net Debt / Equity | — | 0.75 | 0.34 | 0.38 | 0.38 | 0.41 | 0.66 | 0.57 | 0.71 | 0.79 | 0.23 |
| Net Debt / EBITDA | 5.38 | 5.38 | 3.44 | 2.28 | 2.11 | 1.76 | 3.37 | 2.67 | 3.39 | 3.63 | 1.12 |
| Debt / FCF | — | 9.50 | 2.88 | 4.06 | 5.86 | 2.62 | 6.33 | 5.07 | 5.05 | 5.49 | 1.38 |
| Interest Coverage | 1.24 | 1.24 | 1.90 | 6.10 | 9.22 | 10.82 | 6.38 | 5.23 | 3.13 | 4.45 | 5.47 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.54 | 2.54 | 2.27 | 2.32 | 2.43 | 2.10 | 2.63 | 2.32 | 2.12 | 2.33 | 2.77 |
| Quick Ratio | 2.01 | 2.01 | 1.34 | 1.29 | 1.43 | 1.40 | 1.68 | 1.47 | 1.39 | 1.51 | 2.03 |
| Cash Ratio | 0.52 | 0.52 | 0.47 | 0.37 | 0.50 | 0.65 | 0.70 | 0.53 | 0.61 | 0.69 | 1.27 |
| Asset Turnover | — | 0.29 | 0.43 | 0.39 | 0.40 | 0.41 | 0.35 | 0.41 | 0.39 | 0.35 | 0.48 |
| Inventory Turnover | 2.16 | 2.16 | 2.24 | 2.12 | 2.18 | 2.64 | 2.36 | 2.49 | 2.49 | 2.46 | 2.76 |
| Days Sales Outstanding | — | 63.30 | 55.04 | 54.42 | 53.47 | 49.83 | 56.84 | 58.88 | 54.61 | 58.82 | 53.15 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | 1.0% | 1.1% | 0.8% | 0.5% | 0.5% | 0.4% | 0.3% | 0.4% | 0.5% | 0.5% | 0.8% |
| Payout Ratio | — | — | 91.2% | 17.9% | 17.6% | 13.1% | 18.9% | 13.6% | 31.0% | 40.1% | 24.8% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | 0.8% | 3.0% | 3.1% | 3.1% | 1.7% | 2.6% | 1.7% | 1.3% | 3.1% |
| FCF Yield | 4.3% | 4.5% | 6.1% | 3.6% | 2.2% | 3.7% | 1.8% | 1.9% | 2.9% | 3.0% | 4.6% |
| Buyback Yield | 5.2% | 5.5% | 2.4% | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 6.3% | 6.6% | 3.1% | 0.5% | 0.6% | 0.4% | 0.3% | 0.5% | 0.5% | 0.5% | 0.8% |
| Shares Outstanding | — | $45M | $47M | $47M | $47M | $47M | $47M | $47M | $47M | $47M | $48M |
UroLift market saturation risk
According to recent financial data, Teleflex trades at a forward P/E of 19.37, which appears to reflect significant market skepticism regarding the long-term growth ceiling of the UroLift platform compared to its historical valuation multiples and the broader diversified medical technology peer group.
The current valuation suggests that investors are discounting the company's ability to pivot toward higher-margin interventional products following the respiratory divestiture. While the forward P/E may appear reasonable, it warrants further investigation into whether the market is correctly pricing the durability of the company's disposable-heavy revenue stream versus its peers.
Based on reported figures, Teleflex's ROIC has fluctuated significantly, reaching a low of -1.4% in 2024Q4 before recovering to 0.4% in 2026Q1, a trend that highlights the difficulty in compounding returns while simultaneously pruning lower-margin business segments from the core portfolio.
The volatility in ROIC appears to be a direct consequence of non-recurring impairment charges and the divestiture of the respiratory business. Investors should monitor whether the company can stabilize its return on invested capital as the portfolio mix shifts toward more specialized, higher-margin interventional devices.
As reported in recent SEC filings, Teleflex's cash conversion cycle reached 154 days in 2026Q1, driven by an inventory turnover profile that suggests ongoing challenges in aligning supply chain management with the fluctuating demand for its specialized medical instruments and procedural kits.
The elevated DIO of 147 days indicates that inventory management remains a critical lever for operational efficiency. The company's ability to optimize this cycle will be essential for improving free cash flow conversion as it moves past the recent portfolio restructuring phase.
Based on the latest quarterly filings, Teleflex successfully reduced its debt-to-equity ratio to 0.06 in 2026Q1, a significant improvement from 0.87 in 2025Q4, which provides the company with substantial balance sheet headroom to pursue future strategic capital allocation or tuck-in acquisitions.
This rapid deleveraging suggests a conservative approach to capital structure management in a period of high interest rate volatility. The current debt profile appears well-positioned to support operational continuity, provided that management avoids overpaying for future growth assets as they did with the NeoTract acquisition.
As indicated by historical financial statements, the P/E ratio is a frequently misapplied metric for Teleflex, as it is heavily distorted by non-cash impairment charges and divestiture-related accounting events that do not reflect the company's underlying operational cash-generating capacity.
Investors should prioritize EV/EBITDA or P/FCF over P/E to better assess the company's true earning power. Relying on GAAP earnings in the current environment likely obscures the durability of the company's disposable-heavy revenue model, which remains a key differentiator from peers reliant on capital equipment sales.
Includes 30+ ratios · 30 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying TFX stock.
Teleflex Incorporated's current P/E ratio is -6.4x. The historical average is 29.5x.
Teleflex Incorporated's current EV/EBITDA is 18.6x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 14.2x.
Teleflex Incorporated's return on equity (ROE) is -24.5%. The historical average is 10.0%.
Based on historical data, Teleflex Incorporated is trading at a P/E of -6.4x. Compare with industry peers and growth rates for a complete picture.
Teleflex Incorporated's current dividend yield is 1.04%.
Teleflex Incorporated has 56.2% gross margin and 12.8% operating margin. Operating margin between 10-20% is typical for established companies.
Teleflex Incorporated's Debt/EBITDA ratio is 6.3x, indicating high leverage. A ratio above 4x may signal elevated financial risk.